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guidelines provide detailed assessments of the impact of obesity in the general population along with aims and strategies for weight loss interventions. 7, 8 However, few studies have focused on the implications of these findings for specific patient populations, including for people with haemophilia (PWH).
Haemophilia is a chronic disease characterized by excessive bleeding, often into joints, which over time may result in progressive arthropathy, functional impairment and chronic joint pain. 9 This constellation of symptoms suggests a potentially aggravating effect of obesity on joint health, as well as barriers towards engagement in physical activity, which may limit an individual's ability to maintain a healthy weight.
Although a comprehensive understanding of the impact of obesity on
haemophilia has yet to be established, emerging evidence from the general population supports consideration of obesity as an important health concern. In this report, we review the literature assessing the impact of obesity on haemophilia-specific outcomes and discuss evidence-based weight management recommendations. We aim to provide a greater understanding of the unique benefits and challenges of weight loss among PWH with coexisting obesity or overweight.
| The obesity epidemic
Within the overall population, the broad impact of obesity on health and well-being has been thoroughly investigated and offers insight into the risk and impact of obesity among PWH. Overweight and obesity in adults are defined as having a body mass index (BMI) of 25-29.9 kg/m 2 and ≥30 kg/m 2 , respectively. In the United States, obesity in adults has risen threefold since the 1970s. 4 More than 35% of US adults have obesity, and an additional 34% of adults are characterized as overweight. 10 Particularly alarming is the dramatic increase in the prevalence of severe obesity (BMI ≥40 kg/m 2 ), which has increased by more than 600% since the 1980s. [10] [11] [12] Prevalence rates are significantly higher among Hispanic adults and non-Hispanic black adults (47.8%), with a strong gender interaction. Within the paediatric population, ideal BMI varies with age, and therefore, weight status is usually determined through comparisons to age-and gender-specific BMI reference standards (i.e BMI percentile or percentage above the 95th percentile). 13 Approximately 31.6% of US children (aged 2-19 years)
meet criteria for overweight (BMI ≥85th percentile of Centers for Disease Control and Prevention [CDC] gender-specific BMI-for-age growth charts from 2000 14, 15 ), including 16.9% categorized as having obesity (BMI ≥95th percentile).
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The medical burden of obesity is profound, accounting for an estimated $3559 in annual per-patient medical expenditures in the general population. 7 A large number of comorbidities associated with excessive weight contribute to this burden. In particular, obesity is an independent risk factor for coronary heart disease, type 2 diabetes, stroke, hypertension, dyslipidaemia, insulin resistance and non-alcoholic fatty liver disease. [16] [17] [18] Obesity is also associated with increased prevalence of numerous cancers, through mechanisms thought to primarily involve hyperinsulinaemia, activation of proinflammatory signalling pathways and alterations in endogenous hormone metabolism. 19 Obesity additionally contributes to disorders of excessive fat mass, such as osteoarthritis and obstructive sleep apnoea, and mental health disorders such as depression, with significant effects on medical care utilization and overall quality of life. 
| LITERATURE REVIEW

| Study selection
This review aimed to summarize literature regarding the prevalence and impact of obesity specifically in PWH. Published studies were identified through a search of literature published within the last 15 years using the electronic databases Scopus and InsightMeme.
Search terms consisted of "obese OR obesity OR overweight OR BMI OR body mass index OR weight" AND "hemophilia OR haemophilia OR hemophiliac OR haemophiliac." References cited within these records were also manually reviewed for additional records of interest.
Records were excluded if they contained no original data, no relevant data, duplicate study data or if they presented data regarding the prevalence of cardiovascular disease without including any control (non-haemophilia) population with which to compare prevalence estimates. Records were categorized by topic, resulting in five distinct categories: obesity prevalence, musculoskeletal health, bleeding tendency, cardiovascular disease and dosing considerations.
A total of 92 records were identified and assessed for inclusion in the analysis by a single reviewer ( Figure 1 ). Of these, 55 were excluded and 37 remained in the final analysis. A comprehensive list of these publications and summary of relevant data are presented in Supplementary Table S1 .
| Obesity prevalence
In PWH, the prevalence of overweight (adults, 19%-59%; children, 15%-21%) and obesity (adults, 18%-36%; children, 17%-22%) is similar to that of the general US population. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Existing evidence suggests minimal correlation between haemophilia severity and risk of obesity, although few studies have evaluated this relationship.
A retrospective review of 132 patient charts from the Mississippi Hemophilia Treatment Center (HTC) found no significant differences in rates of overweight or obesity between those with severe vs mild or moderate haemophilia. 22 Furthermore, conflicting reports were obtained from a Dutch postal survey that found severe haemophilia to be associated with lower rates of overweight 32 and a Canadian paediatric chart review that found severe haemophilia to be associated with higher rates of obesity. 33 Existing evidence also suggests a 
| Musculoskeletal health
Many studies regarding haemophilia and obesity have focused on complications of the musculoskeletal system, as joint pain and functional disability are critical complications of haemophilia and intuitively linked to obesity through potentially convergent effects on joint damage and range of motion (ROM). Haemophilic joint disease is a consequence of recurrent joint bleeding, which over time causes intra-articular blood-induced damage of the cartilage and synovium, in processes resembling both osteoarthritis and rheumatoid (inflammatory) arthritis. 9 Obesity and adiposity are also strongly associated with osteoarthritis and musculoskeletal pain, through pathways triggered primarily by mechanical stress and subsequent cartilage degradation. 35 Systemic adipose factors have also been implicated in obesityinduced osteoarthritis, particularly regarding non-weight-bearing joints such as the hands and elbows, and may mediate a distinct pathway contributing to joint disease. 37 Additionally, a follow-up study was designed to track longitudinal outcomes of childhood obesity (over a 10-year period) using UDC data from 6347 males with haemophilia aged 2 to 20 years. 26 Individuals with obesity at baseline exhibited a lower initial ROM score, as well as a faster rate of mobility loss in the lower limbs, suggesting an accelerating effect of obesity on the loss of ROM in the weight-bearing joints. An additional study investigating ROM limitations assessed numbers of target joints and joints with reduced mobility among children and young adults with haemophilia from a single US centre. 38 Results of this analysis found individuals with BMI at or above the 85th percentile to exhibit significantly greater odds (3.4, 95% CI, 1.1-10.7) of having at least one target joint or joint with ROM outside the range of normal, consistent with important effects of obesity on haemophilic joint damage.
In addition to these reports of mobility loss, functional correlates of physical disability were investigated in a study of 6419 young males with haemophilia (aged ≤18 years) using UDC data collected between 1998 and 2008. 24 As determined by multivariate analysis, individuals with obesity reported significantly greater levels of disability, as measured using three independent indicators (i.e having lost more than 11 days of work or school during the past year; requiring use of a cane, crutches or a walker; and requiring use of a wheelchair). Lower limb functional limitations were further supported by an analysis of functional ability using the Hemophilia Activities List (HAL) patientreported outcome instrument in a study from a single institution in the Netherlands. 39 Compared with adults without obesity, those with obesity reported significantly lower HAL scores on all domains related to function of the lower extremities (basic lower extremity function, complex lower extremity function, lying/sitting/kneeling/standing and leg functions).
| Bleeding tendency
Existing evidence has not demonstrated a consistent correlation be- ), as well as relatively small sample sizes, limit our ability to form strong conclusions based on these data. Similarly, a separate case report examined rates of bleeding before and after substantial weight loss in a man with both severe obesity and severe haemophilia who had undergone bariatric surgery. 43 Although his overall rate of bleeding did not change, the authors report that he experienced notably fewer joint bleeds, and an increase in soft tissue and muscle bleeds was largely attributed to increased physical activity.
| Cardiovascular disease and risk factors
Because of the important role of obesity as a risk factor for coronary heart disease, assessment of the impact of obesity in any patient population is likely to include a consideration of cardiovascular health.
Haemophilia has traditionally been viewed as offering protection from thrombosis, due to the induction of a hypocoagulable state, and has been associated with a significantly reduced risk for venous thromboembolism. However, the relationship between haemophilia and cardiovascular risk is not as well understood. 44 Numerous assessments of cardiovascular risk among PWH compared with the general population have been performed, although no consensus has been reached as to whether a protective effect of haemophilia is conferred. Our search identified 13 records that reported on cardiovascular risk among PWH compared with the general population. Of those that assessed the relative prevalence of cardiovascular disease or mortality, one supported a protective effect of haemophilia, three indicated a potential negative effect of haemophilia, and two found no substantial effect of haemophilia. [45] [46] [47] [48] [49] [50] However, methodological concerns and mostly small sample sizes limit interpretation of these results and suggest the need for a large prospective study.
Many studies have also investigated the effects of haemophilia on specific risk factors for cardiovascular disease, as assessment of individual factors may clarify the understanding of the relationship between haemophilia and overall cardiovascular risk. In general, assessments of risk factors including diabetes, dyslipidaemia and atherosclerosis reflect many of the same methodological limitations and inconclusive or contradictory results that have been reported in the context of cardiovascular disease. [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] However, hypertension appears to be a notable exception, as existing evidence consistently supports an increased prevalence among PWH. 45, 46, 49, [54] [55] [56] [57] Although data regarding a pathogenic mechanism of hypertension in the context of haemophilia are lacking, recent studies among large cohorts have reported an increase in prevalence compared with the general population, ranging from 23% to 61%. Of note, hypertension may be particularly worrisome in the context of haemophilia due to a strong correlation with intracranial haemorrhage, a potentially lethal bleeding event. Among PWH with coexisting obesity, accumulating evidence demonstrates a significantly increased in vivo recovery of factor replacement products. 59, 60 Because fatty tissue contains less blood than lean body mass, dosing based on body weight likely overestimates total blood volume, leading to higher recovery and a potential for greater trough activity levels compared with equivalent per kilogram dosing in individuals of normal weight. However, the only pivotal registration study in which clinical outcomes were assessed across weight categories demonstrated similar annualized bleeding rates in obese and non-obese individuals when dosed by body weight. 40 In contrast, idealweight-based dosing of FVIII has been reported for routine prophylactic infusions as well as continuous infusion during surgery among small populations of people with haemophilia A and is associated with similar pharmacokinetics (peak level and half-life) compared with standard dosing regimens. 61, 62 In the absence of any studies in which patients were randomized to different trough levels, the issue of the most appropriate minimal factor activity target for prophylaxis remains unclear.
| Pharmacokinetics and dosing considerations
Furthermore, the presence of lower extremity joint problems among overweight individuals with haemophilia might suggest that this population could benefit from slightly higher factor activity.
Given that haemophilia treatment is based on body weight, it would follow that moderate weight loss could result in substantial (Table 1) . Achieving a 5% to 10% reduction in initial weight would potentially result in a direct and parallel reduction in factor cost that could more than offset the costs of any weight loss interventions. Even if the individual were to gradually gain back weight, the net savings in the short-term would still be significant.
An additional mechanism through which obesity may influence treatment outcomes is through potential effects on individuals' ability to self-infuse clotting factor products or bypassing agents. Analysis of a large number of PWH (N=10 814) within the UDC database indicated significantly lower rates of self-infused and home-infused treatments among individuals with obesity vs those of normal weight, which may be attributed to challenges in visualizing veins due to excessive adiposity. 27 Because an inability to infuse in the home setting may limit individuals' access to timely treatment for acute bleeding episodes or adherence to a routine dosing regimen, weight loss may be an important means to improve treatment-related outcomes among some PWH with coexisting obesity. and establish behavioural changes that promote adherence to these changes in diet and exercise. 63 More intensive approaches, including pharmacotherapy and bariatric surgery, are recommended for individuals with obesity-related comorbid conditions and/or higher weight status (Table 2) , especially for those with severe obesity and in situations in which behavioural therapy alone has been insufficient to achieve meaningful weight loss. Obesity medicine specialists may be helpful in determining whether pharmacotherapy or bariatric surgery (assuming a careful consideration of surgical risks) may be warranted; of note, for PWH, appropriate haemostatic coverage during surgery should be administered in the perioperative setting under the direction of the HTC.
| APPLICATION OF GENERAL GUIDELINES FOR WEIGHT MANAGEMENT
A reduction in caloric intake should be the main component of any weight loss intervention, and may be achieved by targeting a specific caloric target (1200-1500 kilocalories/day for women and 1500-1800 kilocalories/day for men) or energy deficit (500 or 750 kilocalories/day) or by restricting consumption of particular foods or food groups. 7, 8 Little evidence suggests that calorie-neutral changes in the macronutrient composition of meals have any direct impact on weight loss. However, consideration of macronutrient consumption may be useful in optimizing adherence or managing specific risks, such as hypertension or cardiovascular disease. 64 Tailoring the prescription for a reduced calorie diet to accommodate patients' personal prefer- Although personal weight loss goals will be influenced by the presence of obesity-related comorbidities and the individual's readiness to make lifestyle changes, sustained loss of as little as 3%-5% of body weight may confer significant metabolic benefits, and loss of 5%-10% of body weight within 6 months is recommended as an initial goal. 7, 8 In the context of comprehensive haemophilia care, routine monitoring of weight and BMI status and establishing standardized protocols for patient referral to nutritionists or other weight management specialists may be important initial steps in identifying and treating weight issues. Because few HTCs have written protocols or guidelines to address weight issues, 72 developing a standardized approach towards collaboration with weight management experts may be an important unmet need. Individuals referred to weight management specialists should be advised that obesity is a chronic condition, and therefore, continued weight maintenance interventions are necessary to prevent weight regain.
| CONCLUSIONS
The study of the broad impact of obesity on haemophilia-specific outcomes is currently in its infancy. However, existing evidence in PWH suggests high obesity prevalence and important effects on joint function, physical disability and venous access for the administration of factor replacement products. Furthermore, evidence from the general population suggests wide-ranging benefits of weight loss. Given weight-based dosing of haemophilia treatment, weight reduction has potential short-term and long-term cost savings that likely exceed costs of weight management interventions.
Future directions of study should include a proof of concept regarding multicomponent therapies in PWH with comorbid obesity to identify weight loss thresholds for improvements in musculoskeletal function and bleeding tendency, in addition to confirming potential pharmacoeconomic savings (Table 3) . Subsequently, large-scale assessments could be performed within existing patient cohort studies to evaluate the impact of weight gain and weight loss on bleeding tendency, which will be necessary to accurately assess weight-related outcomes. A greater understanding of clinical outcomes associated with weight management approaches and patient and HCP perceptions regarding weight issues may facilitate the establishment of evidence-based weight management guidelines specific to the haemophilia experience. In the context of our current understanding of weight issues in PWH, HCPs involved in the comprehensive care of PWH should be aware of how to accurately monitor weight status and collaborate with weight management specialists to implement weight loss interventions for their patients with overweight or obesity.
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